1. Application of 3D Mass Spectrometry Imaging to TKIs
- Author
-
Lavinia Morosi, Simonetta Andrea Licandro, Francesca Falcetta, Eugenio Erba, Sonja Visentin, Paolo Ubezio, Enrico Davoli, Roberta Frapolli, Massimo Zucchetti, Silvia Giordano, Maurizio D'Incalci, Cristina Matteo, Morosi, L, Giordano, S, Falcetta, F, Frapolli, R, Licandro, S, Matteo, C, Zucchetti, M, Ubezio, P, Erba, E, Visentin, S, D'Incalci, M, and Davoli, E
- Subjects
0301 basic medicine ,Pathology ,medicine.medical_specialty ,medicine.drug_class ,Neoplasms, Mesothelial ,Pleural Neoplasms ,Metal Nanoparticles ,Mass spectrometry ,Mass Spectrometry ,Tyrosine-kinase inhibitor ,Mass spectrometry imaging ,Animals, Humans, Imaging, Three-Dimensional, Imatinib Mesylate, Mass Spectrometry, Metal Nanoparticles, Mice, Neoplasms, Mesothelial, Pleural Neoplasms, Protein Kinase Inhibitors, Tissue Distribution, Xenograft Model Antitumor Assays ,Mice ,03 medical and health sciences ,Imaging, Three-Dimensional ,0302 clinical medicine ,medicine ,Animals ,Humans ,Tissue Distribution ,Pharmacology (medical) ,Pleural Neoplasm ,Protein Kinase Inhibitors ,neoplasms ,Pharmacology ,Molecular mass ,Chemistry ,Imatinib ,Xenograft Model Antitumor Assays ,respiratory tract diseases ,030104 developmental biology ,Imatinib mesylate ,Tissue sections ,030220 oncology & carcinogenesis ,Imatinib Mesylate ,Cancer research ,Gold ,medicine.drug - Abstract
Mass spectrometry imaging (MSI) allows visualization of endogenous and exogenous compound in tissue sections based on its molecular mass. The 3D reconstruction by MSI provides a more informative description of the tumor drug distribution compared to the high-performance liquid chromatography method, highlighting the heterogeneity of intratumor drug concentration. This additional information can be important in understanding chemoresistance to target agents. Here, we present the 3D visualization of the tyrosine kinase inhibitor (TKI), imatinib, in a xenograft model of resistant malignant pleural mesothelioma.
- Published
- 2017